IFNα induces the expression of the cyclin-dependent kinase inhibitor p21 in human prostate cancer cells

Oncogene

Volumn 14, Issue 10, 1997, Pages 1165-1170

  Hobeika, Amy C ^a   Subramaniam, Prem S ^a   Johnson, Howard M ^a  

^a UNIVERSITY OF FLORIDA   (United States)

Author keywords

Cyclin dependent kinase 2; Cyclin E; Interferon ; p21; Prostate cancer

Indexed keywords

ALPHA INTERFERON; ANTIMITOTIC AGENT; CYCLIN DEPENDENT KINASE; CYCLIN DEPENDENT KINASE INHIBITOR; CYCLIN E; PROTEIN P21; ANTINEOPLASTIC AGENT; CDK2 PROTEIN, HUMAN; CDKN1A PROTEIN, HUMAN; CYCLIN DEPENDENT KINASE 2; CYCLIN DEPENDENT KINASE INHIBITOR 1A; CYCLINE; PROTEIN SERINE THREONINE KINASE;

ARTICLE; CANCER CELL; CANCER CELL CULTURE; CELL CYCLE; CELL CYCLE G1 PHASE; CELL CYCLE S PHASE; CELL GROWTH; CELL PROLIFERATION; COLONY FORMATION; CONTROLLED STUDY; DNA SYNTHESIS INHIBITION; ENZYME ACTIVITY; FLOW CYTOMETRY; GENE INDUCTION; GENE MUTATION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; TUMOR SUPPRESSOR GENE; BIOSYNTHESIS; CELL DIVISION; DRUG EFFECT; MALE; METABOLISM; MUTATION; PATHOLOGY; PROSTATE TUMOR;

ANTINEOPLASTIC AGENTS; CDC2-CDC28 KINASES; CELL CYCLE; CELL DIVISION; CYCLIN-DEPENDENT KINASE 2; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLIN-DEPENDENT KINASES; CYCLINS; FLOW CYTOMETRY; GENES, TUMOR SUPPRESSOR; HUMANS; INTERFERON-ALPHA; MALE; MUTATION; PROSTATIC NEOPLASMS; PROTEIN-SERINE-THREONINE KINASES;

EID: 0030609969     PISSN: 09509232     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.onc.1200939     Document Type: Article

References (26)

1. Blalock JE, Georgiades JA, Langford MP and Johnson HM. (1980). Cell Immunol., 49, 390-394.
2. Bookstein R, Shew J-Y, Chen P-L, Scully P and Lee W-H. (1990). Science, 247, 712-715.
3. Burke LC, Bybee A and Thomas NS. (1992). Oncogene, 7, 783-788.
4. Bybee A and Thomas NS. (1992). Biochim. Biophys. Acta, 1137, 73-76.
5. Cavenee WK and White RL. (1995). Sci. Am., March, 72-79.
6. Creasy AA, Bartholomew JC and Merigan TC. (1980). Proc. Natl. Acad. Sci. USA, 77, 1471-1475.
7. Dong J-T, Lamb PW, Rinker-Schaeffer CW, Vukanovic J, Ichikawa T, Isaacs JT and Barrett JC. (1995). Science, 268, 884-886.
8. Familletti PC, Rubinstein S and Petska S. (1981). Methods Enzymol., 78, 387-394.
9. Garnick MB. (1994). Sci. Am., April, 72-81.
10. Gutterman JU. (1994). Proc. Natl. Acad. Sci. USA, 91, 1198-1205.
11. Isaacs WB, Carter BS and Ewing CM. (1991). Cancer Res., 51, 4716-4720.
12. Kumar R and Atlas I. (1992). Proc. Natl. Acad. Sci. USA, 89, 6599-6603.
13. Nakajima Y, Konno S, Perruccio Y, Chen JM, Wu S, An J, Chiao M, Choudhury M, Mallouh C and Muraki J. (1994). Biochem. Biophys. Res. Commun., 200, 467-474.
14. Netto GJ and Humphrey PA. (1994). Am. J. Clin. Pathol., 102, S57-S64.
15. Ohtsubo M, Theodoras AM, Schumacher J, Roberts JM and Pagano M. (1995). Mol. Cell. Biol., 15, 2612-2624.
16. Parker SL, Tong T, Bolden S and Wingo PA. (1996). CA Cancer J. Clin., 46, 5-27.
17. Pines J and Hunter T. (1995). Cycle Control. Hutchinson C and Glover DM (eds). Oxford University Press: New York, pp. 144-176.
18. Pontzer CH, Bazer FW and Johnson HM. (1991). Cancer Res., 51, 5304-5307.
19. Resnitzky D, Tiefenbrun N, Berissi H and Kimchi A. (1992). Proc. Natl. Acad. Sci. USA, 89, 402-406.
20. Roos G, Leanderson T and Lundgren E. (1984). Cancer Res., 44, 2358-2362.
21. Sica G, Fabbroni L, Castagnetta L, Cacciatore M and Pavone-Macaluso M. (1989). Urol. Res., 17, 111-115.
22. Subrmaniam PS and Johnson HM. J Interferon Cytokine Res., in press.
23. Tamm I, Jasny BR and Pfeffer LM. (1987). Mechanisms of Interferon Actions Volume II. Pfeffer LM (ed). CRC Press: Boca Raton, FL, pp. 25-57.
24. Thomas NS, Burke LC, Bybee A and Linch DC. (1991). Oncogene, 6, 317-322.
25. Tiefenbrun N, Melamed D, Levy N, Resnitzky D, Hoffmann I, Reed SI and Kimchi A. (1996). Mol. Cell. Biol., 16, 3934-3944.
26. Tsai L-H, Lees E, Faha B, Harlow E and Riabowol K. (1993). Oncogene, 8, 1593-1602.